159 related articles for article (PubMed ID: 11526509)
1. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
3. Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest.
Justman QA; Clinton GM
J Biol Chem; 2002 Jun; 277(23):20618-24. PubMed ID: 11934884
[TBL] [Abstract][Full Text] [Related]
4. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
Staverosky JA; Muldoon LL; Guo S; Evans AJ; Neuwelt EA; Clinton GM
Clin Cancer Res; 2005 Jan; 11(1):335-40. PubMed ID: 15671564
[TBL] [Abstract][Full Text] [Related]
5. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
6. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
7. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
8. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
9. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.
Komurasaki T; Toyoda H; Uchida D; Morimoto S
Oncogene; 1997 Dec; 15(23):2841-8. PubMed ID: 9419975
[TBL] [Abstract][Full Text] [Related]
10. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
11. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
Sanderson MP; Dempsey PJ; Dunbar AJ
Growth Factors; 2006 Jun; 24(2):121-36. PubMed ID: 16801132
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
Ewald JA; Coker KJ; Price JO; Staros JV; Guyer CA
Exp Cell Res; 2001 Aug; 268(2):262-73. PubMed ID: 11478852
[TBL] [Abstract][Full Text] [Related]
13. Receptor binding specificities of Herstatin and its intron 8-encoded domain.
Shamieh LS; Evans AJ; Denton MC; Clinton GM
FEBS Lett; 2004 Jun; 568(1-3):163-6. PubMed ID: 15196940
[TBL] [Abstract][Full Text] [Related]
14. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.
Kumagai T; Davis JG; Horie T; O'Rourke DM; Greene MI
Proc Natl Acad Sci U S A; 2001 May; 98(10):5526-31. PubMed ID: 11320205
[TBL] [Abstract][Full Text] [Related]
15. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor.
Hu P; Feng J; Zhou T; Wang J; Jing B; Yu M; Hu M; Zhang X; Shen B; Guo N
J Cell Physiol; 2005 Dec; 205(3):335-43. PubMed ID: 15920761
[TBL] [Abstract][Full Text] [Related]
16. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
17. The role of erbB-2 and its ligands in growth control of malignant breast epithelium.
Lupu R; Dickson RB; Lippman ME
Princess Takamatsu Symp; 1991; 22():49-60. PubMed ID: 1688228
[TBL] [Abstract][Full Text] [Related]
18. The protein kinase C inhibitor Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] potentiates agonist-induced mitogen-activated protein kinase activation through tyrosine phosphorylation of the epidermal growth factor receptor.
Shah BH; Olivares-Reyes JA; Catt KJ
Mol Pharmacol; 2005 Jan; 67(1):184-94. PubMed ID: 15465928
[TBL] [Abstract][Full Text] [Related]
19. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
20. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
